Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies

NCT02433626 is registered in ClinicalTrials.gov with Critical Outcome Technologies Inc. as lead sponsor.

NCT NCT02433626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02433626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies
Lead sponsor
Critical Outcome Technologies Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
December 31, 2015
Completion date
June 30, 2020
Enrollment
51 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, head and neck cancer, hnscc, lung cancer, ovarian cancer, pancreatic cancer, peritoneal cancer